Skip to main content

Table 1 Participant baseline demographic characteristics

From: Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

 

High-dose ECV19

Low-dose ECV19

Placebo

Characteristics: N

100

100

29

Sex

 Male: no. (%)

44 (44.0)

62 (62.0)

18 (62.1)

 Female: no. (%)

56 (56.0)

38 (38.0)

11 (37.9)

Age years (y)

 All (19–67 y): mean (SD)

40.8 (12.5)

42.0 (13.1)

39.6 (10.9)

 19–34 y: no. (%)

29 (29.0)

36 (36.0)

11 (37.9)

 35–64 y: no. (%)

69 (69.0)

62 (62.0)

18 (62.1)

 65–67 y: no. (%)

2 (2.0)

2 (2.0)

0 (0.0)

BMI: mean (SD)

23.8 (2.8)

23.8 (3.0)

22.8 (2.6)

  1. The race or ethnic group of all participants was Korean (Asian)